Targeted Drug Delivery Via Human Epidermal Growth Factor Receptor for Sustained Release of Allyl Isothiocyanate

Author(s): David Encinas-Basurto, Josue Juarez, Miguel A. Valdez, Maria G. Burboa, Silvia Barbosa, Pablo Taboada*

Journal Name: Current Topics in Medicinal Chemistry

Volume 18 , Issue 14 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


In this study, allyl-isothiocyanate (AITC)-loaded Polylactic-Co-Glycolic Acid (PLGA) Nanoparticles (NPs) were prepared for targeting epithelial squamous carcinoma cells using a specific antibody targeting the Epidermal Growth Factor (EGF) receptor overexpressed on the cell membranes. AITC-loaded PLGA NPs showed more effective anticancer properties compared with free AITC, and their cytotoxicity was even more pronounced when the anti-EGFR antibody was covalently attached to the NPs surface. This targeting ability was additionally tested by co-culturing cervical HeLa cells, with very few EGFR on the membranes, and epithelial squamous carcinoma A431 cells, which largely overexpressed EFGR, being observed the specific localization of the antibody-functionalized AITC-loaded PLGA NPs solely in the latter types of cells, whereas non-functionalized NPs were distributed randomly in both cell types in much lesser extents. Thus, our findings support the development of drug delivery strategies that enhances the delivery of anti-cancer natural compounds to tumor tissue, in this case, by targeting specific tumor cell receptors with cell-specific ligands followed by tumor sensitization.

Keywords: Allyl isothiocyanate, PLGA, Target delivery, Epidermal growth factor, Surface modification, Isothiocyanates.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [1252 - 1260]
Pages: 9
DOI: 10.2174/1568026618666180810150113
Price: $65

Article Metrics

PDF: 29
PRC: 1